Abstract
Hyperhomocysteinemia is increasingly recognized as an independent risk factor for several cerebral, vascular, ocular, and agerelated disorders. Whether it is a cause or a consequence or a mere marker necessitates further clarification. This review focuses on the pathophysiological aspects of homocysteines involvement in neurodegenerative and neuropsychiatric disorders and complications. The pharmacological agents (antiepileptic drugs, L-DOPA) augment the homocysteine levels, thus, raising concern for physicians. The mechanisms underlying the enhanced homocysteine levels and its related pathophysiological cascades remain poorly understood, inspite of numerous epidemiological and research studies that have been carried out in recent years. This article will review the current understanding of these underlying mechanisms and the research being carried with homocysteine as a core molecule.
Keywords: Homocysteine, homocysteine thiolactone, hyperhomocysteinemia, diagnostic marker, prognostic marker, predictive marker, L-DOPA, HCY, Folic acid, Pyridoxine, Cobalamin, Trimethylglycine, Choline, Melatonin, MK-801
CNS & Neurological Disorders - Drug Targets
Title: Homocysteine in Neurological Disease: A Marker or a Cause?
Volume: 10 Issue: 3
Author(s): Suruchi Khanna, Puneet Kapoor, K. K. Pillai and Divya Vohora
Affiliation:
Keywords: Homocysteine, homocysteine thiolactone, hyperhomocysteinemia, diagnostic marker, prognostic marker, predictive marker, L-DOPA, HCY, Folic acid, Pyridoxine, Cobalamin, Trimethylglycine, Choline, Melatonin, MK-801
Abstract: Hyperhomocysteinemia is increasingly recognized as an independent risk factor for several cerebral, vascular, ocular, and agerelated disorders. Whether it is a cause or a consequence or a mere marker necessitates further clarification. This review focuses on the pathophysiological aspects of homocysteines involvement in neurodegenerative and neuropsychiatric disorders and complications. The pharmacological agents (antiepileptic drugs, L-DOPA) augment the homocysteine levels, thus, raising concern for physicians. The mechanisms underlying the enhanced homocysteine levels and its related pathophysiological cascades remain poorly understood, inspite of numerous epidemiological and research studies that have been carried out in recent years. This article will review the current understanding of these underlying mechanisms and the research being carried with homocysteine as a core molecule.
Export Options
About this article
Cite this article as:
Khanna Suruchi, Kapoor Puneet, K. Pillai K. and Vohora Divya, Homocysteine in Neurological Disease: A Marker or a Cause?, CNS & Neurological Disorders - Drug Targets 2011; 10 (3) . https://dx.doi.org/10.2174/187152711794653797
DOI https://dx.doi.org/10.2174/187152711794653797 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tamoxifen as a Powerful Neuroprotectant in Experimental Stroke and Implications for Human Stroke Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Role of Cytokines and Trophic Factors in the Pathogenesis of Diabetic Retinopathy
Current Diabetes Reviews Subthreshold Laser Therapy for Diabetic Macular Edema: Metabolic and Safety Issues
Current Medicinal Chemistry Asymmetric Dimethylarginine (ADMA): A Promising Biomarker for Cardiovascular Disease?
Current Topics in Medicinal Chemistry Drugs Designed to Improve Endothelial Function: Effects on Erectile Dysfunction
Current Pharmaceutical Design Importance of Pharmacology Knowledge by Dieticians
Current Nutrition & Food Science Endothelin Receptor Antagonists as Disease Modifiers in Systemic Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Current Drug Therapy Clinical Strategies for the Blockade of IL-18 in Inflammatory Bowel Diseases
Current Drug Targets Phytocompounds as Potential Agents to Treat Obesity-Cardiovascular Ailments
Cardiovascular & Hematological Agents in Medicinal Chemistry Medicinal Chemistry of the Epigenetic Diet and Caloric Restriction
Current Medicinal Chemistry Recent Advancement in the Treatment of Cardiovascular Diseases: Conventional Therapy to Nanotechnology
Current Pharmaceutical Design Anti-Inflammatory and Antioxidant Properties of Piper Species: A Perspective from Screening to Molecular Mechanisms
Current Topics in Medicinal Chemistry Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Haptoglobin Phenotype May Alter Endothelial Progenitor Cell Cluster Formation in Cerebral Small Vessel Disease
Current Neurovascular Research Meet Our Section Editor
Current Medicinal Chemistry Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome
Current Vascular Pharmacology Lipid Rafts and Redox Regulation of Cellular Signaling in Cholesterol Induced Atherosclerosis
Current Cardiology Reviews Current Drug Targets for Antihyperlipidemic Therapy
Mini-Reviews in Medicinal Chemistry Editorial (Novel Therapies and Botanical and Mechanical Approaches for Management of Cardiovascular Disease)
Recent Patents on Cardiovascular Drug Discovery